[go: up one dir, main page]

WO1997034627A3 - Protection of hemopoietic cells during chemotherapy or radiotherapy - Google Patents

Protection of hemopoietic cells during chemotherapy or radiotherapy Download PDF

Info

Publication number
WO1997034627A3
WO1997034627A3 PCT/IB1997/000499 IB9700499W WO9734627A3 WO 1997034627 A3 WO1997034627 A3 WO 1997034627A3 IB 9700499 W IB9700499 W IB 9700499W WO 9734627 A3 WO9734627 A3 WO 9734627A3
Authority
WO
WIPO (PCT)
Prior art keywords
radiotherapy
hemopoietic cells
cells during
protection
during chemotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB1997/000499
Other languages
French (fr)
Other versions
WO1997034627A2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of WO1997034627A2 publication Critical patent/WO1997034627A2/en
Publication of WO1997034627A3 publication Critical patent/WO1997034627A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of promoting regeneration of hemopoietic cells in a subject undergoing chemotherapy or radiotherapy, which method includes administering to the subject an angiotensin-converting enzyme inhibitor, the amount being effective to reduce the proliferation of hemopoietic cells during or after said chemotherapy or radiotherapy.
PCT/IB1997/000499 1996-03-19 1997-03-19 Protection of hemopoietic cells during chemotherapy or radiotherapy Ceased WO1997034627A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61648996A 1996-03-19 1996-03-19
US08/616,489 1996-03-19

Publications (2)

Publication Number Publication Date
WO1997034627A2 WO1997034627A2 (en) 1997-09-25
WO1997034627A3 true WO1997034627A3 (en) 1997-12-18

Family

ID=24469683

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1997/000499 Ceased WO1997034627A2 (en) 1996-03-19 1997-03-19 Protection of hemopoietic cells during chemotherapy or radiotherapy

Country Status (1)

Country Link
WO (1) WO1997034627A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852316B2 (en) 1998-08-18 2005-02-08 Queen Mary & Westfield College Cancer treatment

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335195B1 (en) 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US6455500B1 (en) 1998-03-10 2002-09-24 University Of Southern California Radiation therapy methods
US7173011B2 (en) 2000-11-20 2007-02-06 University Of Southern California Radiation therapy methods
JP3728400B2 (en) * 1998-03-10 2005-12-21 ユニヴァースティ オブ サザーン カリフォルニア Various methods of improved radiation therapy
WO1999058140A1 (en) * 1998-05-11 1999-11-18 University Of Southern California Methods to increase white blood cell survival after chemotherapy
US6762167B1 (en) 1998-05-11 2004-07-13 University Of Southern California Methods for treating a patient undergoing chemotherapy
US7338938B2 (en) 1999-05-10 2008-03-04 University Of Southern California Methods for treating a patient undergoing chemotherapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114926A (en) * 1986-07-18 1992-05-19 Institut National De La Sante Et De La Recherche Medicale Tetrapeptide inhibiting the entry into cycle of hemopoietic stem cells processes for its preparation, and its uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114926A (en) * 1986-07-18 1992-05-19 Institut National De La Sante Et De La Recherche Medicale Tetrapeptide inhibiting the entry into cycle of hemopoietic stem cells processes for its preparation, and its uses

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AZIZI M ET AL: "Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline", JOURNAL OF CLINICAL INVESTIGATION, 97 (3). 1996. 839-844., XP002042150 *
MOORE M A S ET AL: "SYNERGY OF INTERLEUKIN 1 AND GRANULOCYTE COLONY-STIMULATING FACTOR IN-VIVO STIMULATION OF STEM-CELL RECOVERY AND HEMATOPOIETIC REGENERATION FOLLOWING 5 FLUOROURACIL TREATMENT OF MICE", PROC NATL ACAD SCI U S A, 84 (20). 1987. 7134-7138., XP002042152 *
MOULDER, JOHN E. ET AL: "Prophylaxis of bone marrow transplant nephropathy with captopril, an inhibitor of angiotensin-converting enzyme", RADIAT. RES., 1993, 136, 404-7, XP002042154 *
RIEGER K-J ET AL: "Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline", BIOCHEMICAL JOURNAL, 296 (2). 1993. 373-378., XP002042151 *
ROUSSEAU A ET AL: "The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme", JOURNAL OF BIOLOGICAL CHEMISTRY, 270 (8). 1995. 3656-3661., XP002042153 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852316B2 (en) 1998-08-18 2005-02-08 Queen Mary & Westfield College Cancer treatment

Also Published As

Publication number Publication date
WO1997034627A2 (en) 1997-09-25

Similar Documents

Publication Publication Date Title
WO1998025597A3 (en) Method for treating and preventing heart failure and ventricular dilatation
HUP9801989A3 (en) Medicament with angiotensin converting enzyme (ace) inhibitors suitable for transdermal application
EP0935415A4 (en) Methods for delivering compounds into a cell
WO1998025598A3 (en) Methods and pharmaceutical compositions for inhibiting tumour cell growth
PL323381A1 (en) Rotamase enzymatic activity inhibitors
ZA973397B (en) Inhibitors of IMPDH enzyme.
NZ316361A (en) Rotamase enzyme activity inhibitors
AU7696098A (en) Substance p inhibitors in combination with nmda-blockers for treating pain
IL128221A0 (en) Cell adhesion inhibitors
AU4499697A (en) Method for treating parasitic diseases with proteasome inhibitors
AU2669897A (en) An improved method and system for performing banking transactions, including home banking
AU5530198A (en) Compositions and methods for stimulating pancreatic islet cell regeneration
ZA973707B (en) Method for treating inflammation.
EP0220107A3 (en) Use of angiotensin-converting enzyme inhibitors in macular degeneration
ZA972843B (en) Cyclic adhesion inhibitors.
WO1997034627A3 (en) Protection of hemopoietic cells during chemotherapy or radiotherapy
GB9425701D0 (en) Enzyme inhibitors
AU4886796A (en) Method for preserving wood and other substrates
AU5333298A (en) Compositions and methods for tumour therapy
AU4692899A (en) Method for pressure treating wood
ZA949839B (en) Composition and method for sewage treatment using fungal and bacterial enzymes
GB9502985D0 (en) Enzyme inhibitors
AU6688798A (en) Method for treating lumber
AU1746297A (en) Tea, kit and method for treating hemorrhoids
ZA974779B (en) Thrombin inhibitors.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97533305

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase